United Therapeutics Corporation

Valuation Analysis

About the Company

United Therapeutics Corporation en bref

United Therapeutics Corporation (UTHR) is currently trading at 467,78 € with a market capitalization of 19,9 Md €. The trailing P/E ratio stands at 19.85x, with a forward P/E of 16.89x. The 52-week range spans from 237,22 € to 531,21 €; the current price is 11.9% below the yearly high. Year-over-year revenue growth stands at -1.6%. The net profit margin stands at 40.62%.

💰 Dividende

United Therapeutics Corporation currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Avis des analystes

13 analystes évaluent United Therapeutics Corporation (UTHR) au consensus : Acheter. L'objectif de cours moyen est de 579,92 €, soit un potentiel de +23.97% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 449,83 € à 653,82 €.

United Therapeutics Corporation : la thèse d'investissement en détail

United Therapeutics Corporation (UTHR) operates in the Healthcare — specifically Drug Manufacturers - Specialty & Generic — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

Le scénario haussier

With a gross margin near 86.58%, the company sits in the top tier of its industry — these are the kinds of structural margins that protect earnings during downturns. Free cash flow is positive and net margins stand at 40.62%, meaning reported earnings translate into real cash that can fund buybacks, dividends or strategic acquisitions. Wall Street consensus sits at Buy with an average price target implying roughly 23.97% upside from current levels — analyst sentiment is firmly constructive.

Le scénario baissier

Revenue is contracting at -1.6% year-over-year — until that trend reverses, valuation is exposed to further downgrades.

À surveiller

• The forward P/E of 16.89x is meaningfully below the trailing 19.85x — analysts expect earnings to step up; the next earnings release is the test.
• The analyst consensus price target implies 23.97% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.

Thèse d'investissement : forces et faiblesses

Aperçu technique

Price shows short-term weakness (below 50d MA) but is still in a longer-term uptrend (above 200d MA).

Profil de risque

The data points to relatively defensive market behavior, elevated short interest (6.04%).

Trading Data

Related Stocks in the Same Sector

Where can I buy United Therapeutics Corporation?

Compare top-rated brokers — low fees, trusted providers, fully regulated.